Table 2.

Clinical characteristics of the Cardiff cohort

Cardiff cohort variables	n
Sample storage [mean ± SD (range)]	106 [6 years ± 4 (1–13)]
Sex (F/M) Ethnicity (WB/Cau)	(75/31) (58/18)
CIS [mean age ± SD (range)]	27 [37 years ± 12 (17–61)]
RRMS [mean age ± SD (range)]	67 [40 years ± 10 (26–70)]
PPMS [mean age ± SD (range)]	6 [54 years ± 10 (38–68)]
SPMS [mean age ± SD (range)]	5 [56 years ± 8 (45–64)]
rs703842 (GG/AG/AA)  CIS rs703842 (GG/AG/AA)  RRMS rs703842 (GG/AG/AA)  PPMS rs703842 (GG/AG/AA)  SPMS rs703842 (GG/AG/AA)	(13/45/48) (3/11/13) (8/30/29) (1/4/1) (0/3/2)
rs12368653 (GG/AG/AA)  CIS rs12368653 (GG/AG/AA)  RRMS rs12368653 (GG/AG/AA)  PPMS rs12368653 (GG/AG/AA)  SPMS rs12368653 (GG/AG/AA)	(33/55/18) (7/13/7) (22/34/11) (1/5/0) (2/3/0)
First inter-attack interval [median (range)]	66 [2 years (0.1–45.4)]
MS duration [median (range)]	84 [2 years (0.1–45.9)]
EDSS [median (range)]	87 [3.0 (0–6.5)]
DMT (yes/no)	40/48
Relapse (yes/no)	5/57
MSSS [median (range)] ARMSSS [median (range)]	74 [2.75 (0.01–9.59)] 87 [4.68 (0.29–9.05)]

AA homozygous adenine, AG heterozygous adenine/guanine, ARMSSS age-related multiple sclerosis severity scale, Cau Caucasian, CIS clinically isolated syndrome, DMT disease-modifying therapy, EDSS expanded disability status scale of Kurtze, GG homozygous guanine, LP lumbar puncture, MSSS multiple sclerosis severity scale, PPMS primary progressive multiple sclerosis, RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, WB white British